Prescription Drugs - Luxembourg

  • Luxembourg
  • in Luxembourg, a small country Europe, is expected to witness a significant growth in its Prescription Drugs market.
  • According to projections, the revenue in this market is set to reach an impressive US$134.20m by the year 2024.
  • This growth is further expected to continue at an annual growth rate of 3.49% (CAGR 2024-2029), resulting in a market volume of US$159.30m by 2029.
  • When compared on a global scale, it is worth noting that United States is anticipated to generate the highest revenue in the Prescription Drugs market, with a staggering US$358.90bn in 2024.
  • In terms of per capita revenue, in Luxembourg is projected to generate approximately US$202.80 per person in the year 2024.
  • This figure showcases the significant economic impact of the Prescription Drugs market in Luxembourg, demonstrating its importance in the overall healthcare sector.
  • Despite being a small country, Luxembourg has a highly advanced and well-regulated pharmaceutical industry, ensuring the availability of a wide range of prescription drugs for its population.

Key regions: Japan, China, Europe, Australia, Canada

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Prescription Drugs (Pharmacies) market in Luxembourg is experiencing steady growth due to several factors.

Customer preferences:
Customers in Luxembourg prefer to purchase prescription drugs from pharmacies due to the convenience and accessibility they offer. Pharmacies in Luxembourg are well-regulated and provide a wide range of prescription drugs, making them the preferred choice for customers. Additionally, customers value the expertise and advice provided by pharmacists, which further contributes to the popularity of pharmacies in the country.

Trends in the market:
One of the key trends in the Prescription Drugs (Pharmacies) market in Luxembourg is the increasing demand for specialty drugs. Specialty drugs are medications that are used to treat complex and chronic conditions, such as cancer, autoimmune diseases, and rare genetic disorders. The rising prevalence of these conditions, coupled with advancements in medical technology, has led to an increased need for specialty drugs. Pharmacies in Luxembourg are adapting to this trend by expanding their range of specialty drugs and partnering with healthcare providers to ensure the availability of these medications. Another trend in the market is the growing focus on e-commerce. With the increasing popularity of online shopping, customers in Luxembourg are also turning to online pharmacies to purchase their prescription drugs. Online pharmacies offer the convenience of home delivery and often provide competitive pricing. This trend is expected to continue as more customers embrace digital platforms for their healthcare needs.

Local special circumstances:
Luxembourg has a high per capita income and a well-developed healthcare system, which contributes to the growth of the Prescription Drugs (Pharmacies) market. The country has a strong pharmaceutical industry, with several multinational companies having their headquarters or production facilities in Luxembourg. This local presence of pharmaceutical companies ensures a steady supply of prescription drugs in the market.

Underlying macroeconomic factors:
Luxembourg has a stable economy with a high standard of living. The country has a favorable business environment and attracts foreign investments, including those in the pharmaceutical sector. The government of Luxembourg also invests in healthcare infrastructure and promotes research and development in the pharmaceutical industry. These macroeconomic factors create a conducive environment for the growth of the Prescription Drugs (Pharmacies) market in Luxembourg. In conclusion, the Prescription Drugs (Pharmacies) market in Luxembourg is witnessing steady growth due to customer preferences for convenience and accessibility, the increasing demand for specialty drugs, the growing focus on e-commerce, the local presence of pharmaceutical companies, and favorable macroeconomic factors. These factors collectively contribute to the development and expansion of the market in Luxembourg.

Methodology

Data coverage:

The data encompasses B2C enterprises. Figures are based on offline and online spending by consumers, including VAT. Not included are B2B and B2G sales, or other pharmaceutical sales through hospitals or retail stores such as supermarkets.

Modeling approach:

Market sizes are determined through a bottom-up approach, building on specific predefined factors for each market market. As a basis for evaluating markets, we use industry associations, third-party studies and reports and survey results from our primary research (e.g., the Statista Global Consumer Survey). In addition, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per country, consumer healthcare spending, GDP and internet penetration. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the relevant market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. For forecasting digital trends such as the online-pharmacy sales share we use exponential trend smoothing and the s-curve method. The main drivers are healthcare expenditure per country and consumer healthcare spending.

Additional notes:

The data is modeled using current exchange rates. The impact of the COVID-19 pandemic and the Russia-Ukraine war are considered at a country-specific level. The market is updated twice a year. GCS data is reweighted for representativeness.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)